<SEC-DOCUMENT>0001096906-25-000095.txt : 20250128
<SEC-HEADER>0001096906-25-000095.hdr.sgml : 20250128
<ACCEPTANCE-DATETIME>20250128152223
ACCESSION NUMBER:		0001096906-25-000095
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250128
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250128
DATE AS OF CHANGE:		20250128

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		25563733

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>utmd-20250128.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fil="http://utahmed.com/20250128" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:i="http://www.xbrl.org/2003/instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEWPD92X]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body>
<div style="display:none">
<ix:header>
<ix:hidden>
<ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="D250128" id="fact1">0000706698</ix:nonNumeric>
<ix:nonNumeric name="dei:AmendmentFlag" contextRef="D250128" id="fact2">false</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="utmd-20250128.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<i:context id="D250128">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2025-01-28</i:startDate>
<i:endDate>2025-01-28</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:14pt Times New Roman;margin:0;text-align:center"><b>UNITED STATES </b></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font:15pt Times New Roman;margin:0;text-align:center"><b>Washington, D.C. &#160;20549</b></p>
<p style="font:15pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:14pt Times New Roman;margin:0;text-align:center"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="D250128" escape="true" id="ixv-352">8-K</ix:nonNumeric></b></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:14pt Times New Roman;margin:0;text-align:center"><b>CURRENT REPORT</b></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:12pt Times New Roman;margin:0;text-align:center"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">Date of Report (date of earliest event reported): &#160;<b><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="D250128" format="ixt:date-monthname-day-year-en" id="ixv-353">January 28, 2025</ix:nonNumeric></b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:14pt"><b><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="D250128" escape="true" id="ixv-354">UTAH MEDICAL PRODUCTS, INC.</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Exact name of registrant as specified in its charter)</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:11pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="D250128" format="ixt-sec:stateprovnameen" id="ixv-355">Utah</ix:nonNumeric></b></p>
</td><td valign="top" style="width:2.6%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:11pt"><b><ix:nonNumeric name="dei:EntityFileNumber" contextRef="D250128" escape="true" id="ixv-356">000-12575</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:11pt"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="D250128" escape="true" id="ixv-357">87-0342734</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(State or other jurisdiction of</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Commission File Number)</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">(IRS Employer</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">incorporation or organization)</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">Identification No.)</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:12pt"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="D250128" escape="true" id="ixv-358">7043 South 300 West</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:11pt Times New Roman;margin:0;text-align:center"><span style="font-size:12pt"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="D250128" escape="true" id="ixv-359">Midvale</ix:nonNumeric></b><b>, </b><b><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="D250128" format="ixt-sec:stateprovnameen" id="ixv-360">Utah</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:12pt"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="D250128" escape="true" id="ixv-361">84047</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Address of principal executive offices)</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Zip code)</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:11pt Times New Roman;margin:0">Registrant&#8217;s telephone number, including area code: &#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:12pt"><b>Phone: </b><b>(</b><b><ix:nonNumeric name="dei:CityAreaCode" contextRef="D250128" escape="true" id="ixv-362">801</ix:nonNumeric></b><b>) </b><b><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="D250128" escape="true" id="ixv-363">566-1200</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:12pt Times New Roman;margin:0;text-align:center"><b>n/a</b></p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Former name or former address, if changed since last report)</p>
</td></tr>
</table>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="D250128" format="ixt-sec:boolballotbox" id="ixv-364">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="D250128" format="ixt-sec:boolballotbox" id="ixv-365">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="D250128" format="ixt-sec:boolballotbox" id="ixv-366">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="D250128" format="ixt-sec:boolballotbox" id="ixv-367">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="D250128" format="ixt-sec:boolballotbox" id="ixv-368">&#9744;</ix:nonNumeric></p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt Times New Roman;margin:0">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&#160;&#160;]</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0"><b>ITEM 2.02&#8212;RESULTS OF OPERATIONS AND FINANCIAL CONDITION</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:12pt Times New Roman;margin:0;margin-left:72pt">Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and twelve months ended December 31, 2024 and forward-looking statements relating to 2024 and beyond as presented in a press release dated January 28, 2025. &#160;</p>
<p style="font:12pt Times New Roman;margin:0;margin-left:72pt">&#160;</p>
<p style="font:12pt Times New Roman;margin:0;margin-left:72pt">The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</p>
<p style="font:12pt Times New Roman;margin:0;margin-left:90pt">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0"><b>ITEM 9.01&#8212;FINANCIAL STATEMENTS AND EXHIBITS</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">The following is filed as an exhibit to this report: &#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:12.56%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Exhibit</b></p>
<p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Number*</b></p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:69.22%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Title of Document</b></p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:12.98%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Location</b></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:12.56%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:center"><b>Item 99.1</b></p>
</td><td valign="top" style="background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:69.22%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify"><span style="font-size:12pt;color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex99z1.htm" style="text-decoration:none">Financial information for Utah Medical Prod</a><a href="utmd_ex99z1.htm" style="text-decoration:none">ucts, Inc. for the three and twelve months ended December 31, 2024</a><a href="utmd_ex99z1.htm" style="text-decoration:none"> and forward-loo</a><a href="utmd_ex99z1.htm" style="text-decoration:none">king statements relating to 2024</a><a href="utmd_ex99z1.htm" style="text-decoration:none"> and beyond as present</a><a href="utmd_ex99z1.htm" style="text-decoration:none">ed in a press release dated January 28, 2025</a><a href="utmd_ex99z1.htm" style="text-decoration:none">.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.98%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:12.56%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:69.22%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:12.98%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">This filing</p>
</td></tr>
</table>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">_______________________________________</p>
<p style="font:9pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:18pt;text-align:justify"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:-18pt">*</kbd>All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document. &#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center"><b>SIGNATURES</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify"><b>UTAH MEDICAL PRODUCTS, INC.</b></p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">Dated:  January 28, 2025</p>
</td><td valign="top" style="width:26.7pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">By:</p>
</td><td valign="top" style="width:218.05pt;border-bottom:0.5pt solid #000000"><p style="font:11pt Times New Roman;margin:0;text-align:justify">/s/ Kevin L. Cornwell</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:26.7pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:218.05pt;border-top:0.5pt solid #000000"><p style="font:11pt Times New Roman;margin:0;text-align:justify">Kevin L. Cornwell, Chief Executive Officer</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/></div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>utmd_ex99z1.htm
<DESCRIPTION>FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2024 AND FORWARD-LOOKING STATEMENTS RELATING TO 2024 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED JANUARY 28, 2025
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEWPD92X]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'><B>EXHIBIT 99.1</B></P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'><B>UTMD Reports Year 2024 and Fourth Quarter Financial Performance</B></P>
<P align=center style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:0pt'>Contact: Brian Koopman (801) 566-1200</KBD><KBD style=margin-left:360pt></KBD>January 28, 2025&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Salt Lake City, Utah &#8211;&nbsp;With Revenues 19% lower, Net Income 17% lower and Earnings Per Share (EPS) 13% lower than in 2023, Utah Medical Products, Inc. (Nasdaq: UTMD) concluded a year of contraction. UTMD&#8217;s stock price declined 27%, more than twice the EPS decline, which allowed the Company an opportunity to repurchase more than 8% of its shares in the open market. &nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&nbsp;or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&nbsp;or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Overview of Results</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>A summary comparison of 4Q and calendar year 2024 income statement category declines relative to the same periods of 2023 follows:</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:198pt'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4Q</KBD><KBD style=margin-left:270pt></KBD> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2024 to 2023 Comparison</FONT> &nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>(October&#8211;December)</FONT> &nbsp;&nbsp;&nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>(January-December)</FONT></P>
<TABLE style=border-collapse:collapse;width:382.5pt;margin-left:27.9pt><TR><TD valign=top style=width:166.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Revenues (Sales):</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt Times New Roman;margin:0;text-indent:30.6pt;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;(26%)</P>
</TD><TD valign=top style=width:99pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;(19%)</P>
</TD></TR>
<TR><TD valign=top style=width:166.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit (GP):</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt Times New Roman;margin:0;text-indent:30.6pt;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;(25%)</P>
</TD><TD valign=top style=width:99pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;(20%)</P>
</TD></TR>
<TR><TD valign=top style=width:166.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income (OI):</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt Times New Roman;margin:0;text-indent:30.6pt;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;(26%) </P>
</TD><TD valign=top style=width:99pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;(19%) </P>
</TD></TR>
<TR><TD valign=top style=width:166.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Income Before Tax (EBT):</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income (NI):</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt Times New Roman;margin:0;text-indent:30.6pt;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;(28%) </P>
<P style='font:11pt Times New Roman;margin:0;text-indent:30.6pt;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;(32%)</P>
</TD><TD valign=top style=width:99pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;(16%) </P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;(17%)</P>
</TD></TR>
<TR><TD valign=top style=width:166.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Earnings Per Share (EPS):</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:6pt;text-indent:30.6pt;margin-right:-6.5pt'> &nbsp;&nbsp;&nbsp;(27%)</P>
</TD><TD valign=top style=width:99pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'> &nbsp;&nbsp;&nbsp;(13%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Despite the lower sales, profit margins in 4Q and year 2024 held up well compared to 4Q and year 2023, for reasons described later in this report:</P>
<TABLE style=border-collapse:collapse;width:461.6pt;margin-left:-1.7pt><TR><TD valign=top style=width:191.6pt><P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>4Q 2024 </P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'><FONT style='border-bottom:1px solid #000000'>(Oct &#8211;&nbsp;Dec)</FONT></P>
</TD><TD valign=top style='width:76.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'>4Q 2023</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(Oct-Dec)</FONT></P>
</TD><TD valign=top style='width:66.7pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'>2024</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(Jan&#8211;Dec)</FONT></P>
</TD><TD valign=top style=width:59.3pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'>2023</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(Jan&#8211;Dec)</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:191.6pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit Margin (GP/ sales):</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>58.1%</P>
</TD><TD valign=top style='width:76.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>57.6% </P>
</TD><TD valign=top style='width:66.7pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>59.0%</P>
</TD><TD valign=top style=width:59.3pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>59.8%</P>
</TD></TR>
<TR><TD valign=top style=width:191.6pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income Margin (OI/ sales):</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>32.0%</P>
</TD><TD valign=top style='width:76.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>32.0%</P>
</TD><TD valign=top style='width:66.7pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>33.2%</P>
</TD><TD valign=top style=width:59.3pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>33.4%</P>
</TD></TR>
<TR><TD valign=top style=width:191.6pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Income Before Tax Margin (EBT/ sales):</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>39.5%</P>
</TD><TD valign=top style='width:76.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>40.7%</P>
</TD><TD valign=top style='width:66.7pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>41.1%</P>
</TD><TD valign=top style=width:59.3pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>40.0%</P>
</TD></TR>
<TR><TD valign=top style=width:191.6pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income Margin (NI/ sales):</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>31.7%</P>
</TD><TD valign=top style='width:76.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>34.8%</P>
</TD><TD valign=top style='width:66.7pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>33.9%</P>
</TD><TD valign=top style=width:59.3pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>33.1%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Because revenue results for any given three-month period in comparison with a previous three-month period are not indicative of comparative results for the year as a whole, investors should focus on the annual results described later in this release. Focusing on the causes of the $9.3 million consolidated worldwide (WW) decline in annual revenues in 2024, the lower sales can be explained in the three following categories:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:212.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Revenue Category:</P>
</TD><TD valign=top style=width:63pt><P align=center style='font:11pt Times New Roman;margin:0'>2024 Sales</P>
<P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>[million $]</FONT></P>
</TD><TD valign=top style=width:63pt><P align=center style='font:11pt Times New Roman;margin:0'>2023 Sales</P>
<P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>[million $]</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=center style='font:11pt Times New Roman;margin:0'>Decline</P>
<P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>[million $]</FONT></P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:10pt Times New Roman;margin:0'>Portion of <FONT style='border-bottom:1px solid #000000'>Total Decline</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:212.4pt><P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>PendoTECH OEM&nbsp;</P>
</TD><TD valign=top style=width:63pt><P align=right style='font:11pt Times New Roman;margin:0'>2.7</P>
</TD><TD valign=top style=width:63pt><P align=right style='font:11pt Times New Roman;margin:0'>8.6</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>(5.9)</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>64%</P>
</TD></TR>
<TR><TD valign=top style=width:212.4pt><P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>OUS Distributors (excluding Filshie)&nbsp;</P>
</TD><TD valign=top style=width:63pt><P align=right style='font:11pt Times New Roman;margin:0'>8.7</P>
</TD><TD valign=top style=width:63pt><P align=right style='font:11pt Times New Roman;margin:0'>10.8</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>(2.1)</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>22%</P>
</TD></TR>
<TR><TD valign=top style='width:212.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>WW Filshie&nbsp;</P>
</TD><TD valign=top style=width:63pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>10.8</FONT></P>
</TD><TD valign=top style=width:63pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>12.3</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>(1.5)</FONT></P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>16%</FONT></P>
</TD></TR>
<TR><TD valign=top style='width:212.4pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Total Above:</P>
</TD><TD valign=top style=width:63pt><P align=right style='font:11pt Times New Roman;margin:0'>22.2</P>
</TD><TD valign=top style=width:63pt><P align=right style='font:11pt Times New Roman;margin:0'>31.7</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>(9.5)</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>102%</P>
</TD></TR>
<TR><TD valign=top style=width:212.4pt><P style='font:11pt Times New Roman;margin:0'>Above % of Total Below:</P>
</TD><TD valign=top style=width:63pt><P align=right style='font:11pt Times New Roman;margin:0'>54%</P>
</TD><TD valign=top style=width:63pt><P align=right style='font:11pt Times New Roman;margin:0'>63%</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>102%</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:212.4pt><P style='font:11pt Times New Roman;margin:0'>Total Consolidated WW Revenues:</P>
</TD><TD valign=top style=width:63pt><P align=right style='font:11pt Times New Roman;margin:0'>40.9</P>
</TD><TD valign=top style=width:63pt><P align=right style='font:11pt Times New Roman;margin:0'>50.2</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>(9.3)</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>100%</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The OUS (Outside the U.S.) Distributor category (item 2 above) included UTMD&#8217;s China distributor for blood pressure monitoring kits for which 2024 shipments were $2.4 million compared to $4.0 million in 2023, representing $1.6 million (75%) of the $2.1 million decline in OUS Distributor revenue (excluding Filshie OUS distributors).</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The decline in WW Filshie device revenues (item 3 above) can be divided into three parts:</P>
<TABLE style=border-collapse:collapse;margin-left:9.9pt><TR><TD valign=top style=width:139.5pt><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Filshie Device Sales</FONT></P>
</TD><TD valign=top style=width:63pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>2024 Sales <FONT style='border-bottom:1px solid #000000'>[million $]</FONT></P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>2023 Sales <FONT style='border-bottom:1px solid #000000'>[million $]</FONT></P>
</TD><TD valign=top style=width:90pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Revenue Decline <FONT style='border-bottom:1px solid #000000'>[million $]</FONT></P>
</TD><TD valign=top style=width:99pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>2024 Revenue <FONT style='border-bottom:1px solid #000000'>Decline from 2023</FONT></P>
</TD></TR>
<TR><TD valign=top style='width:139.5pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Domestic Direct (to U.S. medical facilities)</P>
</TD><TD valign=top style=width:63pt><P align=center style='font:11pt Times New Roman;margin:0'>4.0</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt Times New Roman;margin:0'>4.8</P>
</TD><TD valign=top style=width:90pt><P align=center style='font:11pt Times New Roman;margin:0'>(0.8)</P>
</TD><TD valign=top style=width:99pt><P align=center style='font:11pt Times New Roman;margin:0'>(15%)</P>
</TD></TR>
<TR><TD valign=top style='width:139.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>OUS Direct (to medical facilities outside the U.S.)</P>
</TD><TD valign=top style=width:63pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>5.3</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>5.8</P>
</TD><TD valign=top style=width:90pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>(0.5)</P>
</TD><TD valign=top style=width:99pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>( 9%)</P>
</TD></TR>
<TR><TD valign=top style='width:139.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OUS distributors</P>
</TD><TD valign=top style=width:63pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>1.5</FONT></P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>1.7</FONT></P>
</TD><TD valign=top style=width:90pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>(0.2)</FONT></P>
</TD><TD valign=top style=width:99pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>(14%)</FONT></P>
</TD></TR>
<TR><TD valign=top style='width:139.5pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Total Filshie Revenues:</P>
</TD><TD valign=top style=width:63pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>10.8</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>12.3</P>
</TD><TD valign=top style=width:90pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>(1.5)</P>
</TD><TD valign=top style=width:99pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>(12%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OUS Direct Filshie revenues were sales by UTMD subsidiaries directly to medical facilities in the UK, France, Ireland, Canada, Australia and New Zealand. Foreign currency exchange (FX) rate changes had a minimally positive impact on 2024 USD revenues compared to 2023.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Despite additional cost-of-living adjustments for employees in 2024 and continued inflation in raw material costs, UTMD was nevertheless able to maintain its GP margin in 2024 by reducing manufacturing personnel, including closing down the second production shift in Utah. The $1.6 million lower sales to UTMD&#8217;s China distributor for blood pressure monitoring kits, $1.3 million of which decline occurred just in 4Q 2024, actually helped UTMD&#8217;s average GP margin as that sales category has the lowest GP margin in UTMD&#8217;s business by quite a bit. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s Operating Income margin was essentially the same in both years, despite retaining its critical mass of sales and marketing (S&amp;M), product development (R&amp;D) and general and administrative (G&amp;A) resources at a higher cost. This occurred because the final 2023 $3,684 G&amp;A expense from amortization of the $21 million identifiable intangible asset (IIA) associated with UTMD&#8217;s 2019 purchase of CooperSurgical Inc&#8217;s (CSI&#8217;s) exclusive right to distribute the Filshie Clip System in the U.S., which was zero in 2024, offset the slightly lower GP margin and higher litigation expenses also captured in G&amp;A expense. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>On the other hand, non-operating income was lower as a result of a new excise tax levied on share repurchases in the U.S. and the fact that UTMD Ltd in Ireland did not enjoy the previous significant 2023 income from renting unused warehouse space in 2024. EPS benefited from UTMD repurchasing over 8% of its shares during the year.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s December 31, 2024 Balance Sheet, in the continued absence of debt, remained strong. After using over $24 million of its cash, specifically $19,968 to repurchase shares, $4,260 to pay stockholder dividends and $231 for new manufacturing equipment and tooling during 2024, ending Cash and Investments declined just $9.9 million to $83.0 million on December 31, 2024 compared to $92.9 million on December 31, 2023. Profitable operations also funded a $907 increase in non-cash working capital despite a $770 reduction in inventories after the previous accumulation as a hedge against supply chain disruption. Stockholders&#8217; Equity (SE) declined $10.9 million as of December 31, 2024 from December 31, 2023 despite an increase of $13.9 million from 2024 Net Income which was offset from the fact that $24.2 million in share repurchases and stockholder dividends reduce SE. </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Foreign currency exchange (FX) rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of calendar year 2024 compared to the end of 2023 and the end of 3Q 2024 follow:</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>12-31-24</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>12-31-23</FONT></P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9-30-24</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'>1.25209</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>1.27386</P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;(1.7%)</P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1.33958</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'> (6.5%)</P>
</TD></TR>
<TR><TD valign=top style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'>1.03505</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>1.10593</P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;(6.4%)</P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1.11429</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'> (7.1%)</P>
</TD></TR>
<TR><TD valign=top style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'>0.61834</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>0.68248</P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>  (9.4%)</P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>0.69312</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'>(10.8%)</P>
</TD></TR>
<TR><TD valign=top style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'>0.69428</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>0.75733</P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;(8.3%)</P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>0.73987</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'>  (6.2%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Revenues (sales)</FONT> - <FONT style='border-bottom:1px solid #000000'>4Q 2024</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 4Q 2024 UTMD worldwide (WW) sales were $9,157 compared to $12,333 in 4Q 2023, $3,176 (25.8%) lower than in 4Q 2023. &#8220;Constant currency&#8221; sales are defined as USD-denominated sales at the same foreign currency exchange rates as in the prior applicable period of time. Total constant currency 4Q 2024 sales were negligibly different. U.S. domestic sales were 14.9% lower, and OUS sales were 38.9% lower in USD terms, than in 4Q 2023.  </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Domestic U.S. sales in 4Q 2024 were $5,735 compared to $6,736 in 4Q 2023. Domestic sales are invoiced in USD and are not subject to FX rate fluctuations. The components of domestic sales include 1) &#8220;direct other device sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;direct Filshie device sales&#8221;. UTMD separates Filshie device sales from other medical device sales direct to medical facilities because of their significance, and the acquisition history. Direct non-Filshie device sales, representing 68% of total domestic sales, were $286 (+7.9%) higher in 4Q 2024 than in 4Q 2023. OEM sales, representing 16% of total domestic sales, were $1,042 (53.5%) lower. Direct Filshie device sales, also representing 16% of total domestic sales, were $245 (20.6%) lower in 4Q 2024 compared to 4Q 2023. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>OUS sales in 4Q 2024 were $3,422 compared to $5,597 in 4Q 2023. Although the GBP was stronger than in the same quarter in 2023, the EUR and CAD were weaker. The net FX constant currency impact resulted in a negligible increase in USD-denominated 4Q 2024 sales. FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 4Q 2024 and 4Q 2023 for revenue purposes follow:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'>4<FONT style='border-bottom:1px solid #000000'>Q 2024</FONT></KBD><KBD style=margin-left:248.1pt></KBD>4<FONT style='border-bottom:1px solid #000000'>Q 2023</FONT> &nbsp;&nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>Change</FONT>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>GBP</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 1.2808</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 1.2411</KBD><KBD style=margin-left:297.7pt></KBD> + 3.2%&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>EUR</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 1.0589</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 1.0857</KBD><KBD style=margin-left:297.7pt></KBD> &nbsp;&nbsp;(2.5%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>AUD</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 0.6546</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 0.6509</KBD><KBD style=margin-left:297.7pt></KBD> + 0.6%&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>CAD</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 0.7166</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 0.7339</KBD><KBD style=margin-left:297.7pt></KBD> &nbsp;( 2.3%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The combined weighted-average positive FX impact on 4Q 2024 foreign currency sales was less than 0.1%. &nbsp;The portion of OUS sales which were invoiced in foreign currencies, in USD terms, were 25% of total consolidated 4Q 2024 sales compared to 32% in 4Q 2023. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OUS sales invoiced in foreign currencies are to direct end-users in Ireland, the UK, France, Canada, Australia and New Zealand, and to OUS distributors of devices manufactured by UTMD subsidiaries in Ireland and the UK. Direct to end-user OUS sales in USD terms in 4Q 2024 which were 48% of all OUS sales, were lower by 11.5%, 4.3%, 18.5%, 23.6% and 15.7% for Ireland, the UK, France, Canada and Australia/New Zealand respectively compared to 4Q 2023. In addition to the FX rate differences in EUR and CAD, these lower numbers primarily reflected lower Filshie device sales. In USD terms, export sales to OUS distributors, which were 52% of OUS sales, were 52% lower than in 4Q 2023. &nbsp;This was </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style=font-size:11pt>primarily because there were no shipments of pressure monitoring kits to UTMD&#8217;s China distributor in 4Q 2024, which are manufactured by UTMD Ltd in Ireland, resulting in $1,587 lower Ireland revenues compared to 4Q 2023. Sales from Ireland to OUS distributors in 4Q 2024 represented 38% of total OUS distributor sales compared to 67% in 4Q 2023. &nbsp;Export sales from the U.S. to OUS distributors are invoiced in USD. Sales to OUS distributors from the U.S. were 11% lower in 4Q 2024 than in 4Q 2023 due in part to a delay in required foreign regulatory approval renewals. &nbsp;&nbsp;</FONT></P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Sales</FONT> -<FONT style='border-bottom:1px solid #000000'>2024 Year</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 2024 UTMD WW USD-denominated sales were $40,903 compared to $50,224 in 2023, which were $9,322 (18.6%) lower than in 2023. The decline resulted from three sales categories highlighted in the summary at the beginning of this release: 1) a $5,938 (69%) decline in OEM sales of biopharma pressure sensors and accessories to PendoTECH, reducing Ireland OUS sales $1,781 and U.S. OEM sales $4,157; 2) excluding Filshie device OUS distributor sales, a $2,124 (20%) decline in OUS distributor sales, including $1,587 lower UTMD Ltd (Ireland) sales to UTMD&#8217;s China distributor of blood pressure monitoring kits; and 3) $1,471 (12%) lower WW sales of Filshie Clip System devices.</P>
<P style='font:11pt Times New Roman;margin:0'>Looking forward to 2025 in those three revenue categories, even though PendoTECH sales were $5.9 million lower in 2024, they were still a reasonably significant $2.7 million. Given the existing year-end PendoTECH open order backlog, and expecting orders for ancillary accessories to remain consistent, but with no additional 2025 pressure sensor orders, UTMD expects PendoTECH revenues may be about $2.0 million lower in 2025. UTMD&#8217;s China distributor for blood pressure monitoring kits has placed a fixed annual order for 2025 which is slightly higher than 2024. With expected regulatory approvals, OUS distributor orders should bounce back in 2025. The Company is projecting OUS Filshie device sales to be higher. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OUS USD-denominated sales in 2024 were $4,562 (20.7%) lower at $17,458 compared to $22,020 in 2023. UTMD Ltd (Ireland) 2024 sales to PendoTECH were $1,781 lower, and to its China distributor for pressure monitoring kits $1,587 lower, than in 2023. Ireland PendoTECH sales, which were $429 in 2024 are expected to be zero in 2025. &nbsp;Based on current order backlog from a fixed annual order, UTMD expects Ireland sales to its China distributor to be slightly higher in 2025 than in 2024. &nbsp;OUS Filshie device sales, both direct to foreign medical facilities and to distributors combined, which are shipped from Ireland or the UK, were $742 lower. UTMD expects the reverse to occur in 2025. Sales of other UTMD devices from the U.S. to OUS distributors were $531 lower in 2024. UTMD also expects this to reverse in 2025. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Sales invoiced in foreign currencies, which were $12,911 when converted to USD, represented 74% of OUS sales and 32% of consolidated total sales. A slightly weaker USD added $113 in OUS foreign currency sales compared to constant currency terms. &nbsp;FX rates for income statement purposes are transaction-weighted averages. The weighted-average FX rates from the applicable foreign currency to USD during 2024 and 2023 for revenue purposes follow:</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'><FONT style='border-bottom:1px solid #000000'> 2024</FONT></KBD><KBD style=margin-left:248.1pt></KBD><FONT style='border-bottom:1px solid #000000'> 2023</FONT> &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>Change</FONT>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>GBP</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 1.2772</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 1.2428</KBD><KBD style=margin-left:297.7pt></KBD> + 2.8%&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>EUR</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 1.0846</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 1.0808</KBD><KBD style=margin-left:297.7pt></KBD> + 0.4%&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>AUD</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 0.6600</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 0.6660</KBD><KBD style=margin-left:297.7pt></KBD> &nbsp;( 0.9%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>CAD</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 0.7313</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 0.7409</KBD><KBD style=margin-left:297.7pt></KBD> &nbsp;( 1.3%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The combined weighted-average favorable FX impact on 2024 foreign currency OUS sales was 0.3%, increasing reported 2024 USD sales by $113 relative to the same foreign currency sales in 2023. &nbsp;In constant currency terms, OUS sales in 2024 were 21.2% lower than OUS sales in 2023. The portion of OUS sales invoiced in foreign currencies in USD terms was 32% of total consolidated 2024 USD sales compared to 30% in 2023. Including the impact of changed FX rates, OUS 2024 direct to end-user sales in USD terms were 7% higher in Ireland, 13% lower in Canada, 17% lower in France and 3% higher in the UK. Direct to end-user sales in Australia, which included New Zealand, were 18% lower.  </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Domestic U.S. sales in 2024 were $23,444 compared to $28,204 in 2023, which was $4,759 (16.9%) lower than in 2023. All three categories of domestic sales were lower, led by U.S. OEM sales which were </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style=font-size:11pt>$3,857 (45.7%) lower than in 2023. Since U.S. PendoTECH sales in this category were $4,157 lower, all other U.S.OEM sales in 2024 were actually $300 higher than in 2023. Since U.S. sales to PendoTECH in 2024 were $2,266, this trend is expected to continue in 2025. Domestic Filshie device sales, representing 17% of total domestic sales, were $729 (15.3%) lower in 2024 compared to 2023. &nbsp;The Company is anticipating a smaller decline in 2025. &nbsp;Direct device sales other than Filshie, representing 63% of total domestic sales, were $173 (1.2%) lower in 2024 than in 2023. In this last category, domestic neonatal device sales were higher but electrosurgery device sales lower. The Company expects domestic sales in this category to be higher in 2025 by a low single digit percentage. </FONT></P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Looking forward to 2025, in summary, UTMD expects total WW consolidated revenues are likely to be lower again, in the low to mid-single percentage digits relative to 2024. &nbsp;UTMD&#8217;s Form SEC 10-K 2024 annual report to be filed in March will provide management&#8217;s projected 2025 financial performance.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Gross Profit (GP)</FONT> &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>GP results from subtracting the costs of manufacturing, quality assurance and receiving materials from suppliers. With an 18.6% decline in 2024 sales, UTMD&#8217;s GP was $5,895 (19.6%) lower than in 2023, and with a 25.8% decline in 4Q 2024 sales, 4Q 2024 GP was $1,775 (25.0%) lower than in 4Q 2023. Despite the facts that supplier costs for raw materials continued to increase and the Company implemented further employee cost-of-living adjustments during 2024, UTMD was able to limit dilution of its GP margin. &nbsp;The 2024 GP margin was 59.0% compared to 59.8% in 2023, and 58.1% in 4Q 2024 compared to 57.6% in 4Q 2023. &nbsp;&nbsp;&nbsp; &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Operating Income (OI)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>OI results from subtracting Operating Expenses (OE) from GP. For the year 2024, OI was $13,594 compared to $16,777 in 2023, a 19.0% decrease. &nbsp;The $3,183 decrease in OI was from the combination of $5,895 lower GP offset by $2,712 lower OE. &nbsp;OI in 4Q 2024 was $2,930 compared to $3,944 in 4Q 2023. &nbsp;The $1,014 lower 4Q 2024 OI was a combination of $1,775 lower GP and $761 lower OE. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OE are comprised of Sales and Marketing (S&amp;M) expenses, G&amp;A expenses and Product Development (R&amp;D) expenses. The following table summarizes OE in 4Q and year 2024 compared to the same periods in 2023 by OE category:</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OE <FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=top style=width:54pt><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>4Q 2024</FONT></P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>4Q 2023</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'> 2024</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'> 2023</FONT></P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>S&amp;M:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'>$ 505</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;5.5</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 475</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;3.9</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ &nbsp;&nbsp;1,901</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;4.6</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ &nbsp; 1,685</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;3.4</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>G&amp;A:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'>1,767 </P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>19.3</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,533</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>20.5</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp; &nbsp;7,835</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>19.2</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;11,016</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>21.9</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>R&amp;D:</FONT></P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;121</FONT></P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.3</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;146</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.2</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;813</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;2.0</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 560</FONT></P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.1</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>Total OE:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'>2,393</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>26.1</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>3,154</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>25.6</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;10,549</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>25.8</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp; 13,261</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>26.4</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The following table summarizes &#8220;constant currency&#8221; OE in 4Q and year 2024 by OE category:</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OE <FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=top style=width:54pt><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>4Q 2024 <FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=top style=width:43.8pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'> 2024 <FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>S&amp;M:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'>$ 505</P>
</TD><TD valign=top style=width:43.8pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ &nbsp;&nbsp;&nbsp;1,899</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>G&amp;A:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'>1,749</P>
</TD><TD valign=top style=width:43.8pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7,765</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>R&amp;D:</FONT></P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;121</FONT></P>
</TD><TD valign=top style=width:43.8pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;813</FONT></P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>Total OE:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'>2,375</P>
</TD><TD valign=top style=width:43.8pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;10,477</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The FX rate change impact on OE in both periods was minor. &nbsp;A stronger GBP increased the Femcare IIA amortization expense included in G&amp;A expense in USD terms by $16 in 4Q 2024 and by $53 for the year 2024, representing most of the full FX rate change impact on OE in both periods. &nbsp; &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>S&amp;M expenses increased in 2024 primarily as a result of cost-of-living salary increases, and an increase in U.S. medical benefits. &nbsp;Constant currency S&amp;M expenses were the same in the 4Q, and $2 lower for the year due to a stronger GBP. R&amp;D increased primarily as a result of validation testing for materials </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style=font-size:11pt>used in biopharma pressure sensors, but also cost-of-living increases. &nbsp;There was no FX rate impact on R&amp;D expenses, as they were solely carried out in the U.S.</FONT></P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>With the exception of salary increases in all departments, the major changes in OE were in the G&amp;A expense category. The main two G&amp;A expense changes were in litigation expense and in the amortization of the $21 million identifiable intangible asset (IIA) associated with UTMD&#8217;s 2019 purchase of CooperSurgical Inc&#8217;s (CSI&#8217;s) exclusive right to distribute the Filshie Clip System in the U.S. The CSI IIA amortization expense, which had been $1,105 per quarter since February 2019, ended in 4Q 2023. &nbsp;The CSI IIA amortization expense was zero in 2024 compared to $368 in 4Q 2023 and $3,684 for the 2023 year. </P>
<P style='font:11pt Times New Roman;margin:0'><A name=_Hlk188166820 />&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Litigation expenses in 2024 were $2,139 (5.2% of sales) compared to $1,660 (3.3% of sales) in 2023. Litigation expenses in 4Q 2024 were $326 (3.6% of sales) compared to $662 (5.4% of sales) in 4Q 2023. Litigation expenses were $479 higher for the 2024 year, and $336 lower in 4Q 2024 compared to the same periods in 2023. &nbsp;Litigation expenses were lower in 4Q 2024 because several still open U.S. Filshie cases have finished with discovery and active motion practice, and are awaiting court decisions on UTMD summary judgment motions. Two cases filed in Florida and Alabama have been won on summary judgment, and others were dismissed prior to the summary judgment phase. If a summary judgment motion is denied, the case would go to trial. No case has gone to trial as yet. While there are currently fewer active cases, and thus less discovery and motion work anticipated in 2025, any cases that must go to trial could drive up litigation expense significantly. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>A division of G&amp;A expenses by location follows: </P>
<TABLE style=border-collapse:collapse;width:447.1pt><TR><TD valign=top style=width:89.95pt><P style='font:11pt Times New Roman;margin:0'>G&amp;A Exp <FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=top style=width:49.15pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2024</FONT></P>
</TD><TD valign=top style='width:35.9pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=top style='width:52pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2023</FONT></P>
</TD><TD valign=top style='width:33.1pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=top style='width:52.1pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> 2024</FONT></P>
</TD><TD valign=top style='width:37.45pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=top style='width:51.75pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> 2023</FONT></P>
</TD><TD valign=top style=width:13.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:32.2pt><P align=center style='font:11pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:89.95pt><P style='font:11pt Times New Roman;margin:0'>IIA Amort - UK:</P>
</TD><TD valign=top style=width:49.15pt><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:2pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:36pt'>509</KBD>&nbsp;</P>
</TD><TD valign=top style='width:35.9pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:23pt'>5.6</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:4pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:37pt'>493</KBD>&nbsp;</P>
</TD><TD valign=top style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>4.0</P>
</TD><TD valign=top style='width:52.1pt;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:4pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:37pt'>2,031</KBD>&nbsp;</P>
</TD><TD valign=top style='width:37.45pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:25pt'>5.0</KBD>&nbsp;</P>
</TD><TD valign=top style='width:51.75pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:1pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:40pt'>1,977</KBD>&nbsp;</P>
</TD><TD valign=top style=width:13.5pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:32.2pt><P align=right style='font:11pt Times New Roman;margin:0'>3.9</P>
</TD></TR>
<TR><TD valign=top style=width:89.95pt><P style='font:11pt Times New Roman;margin:0'>IIA Amort&#8211; CSI:</P>
</TD><TD valign=top style=width:49.15pt><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:36pt'>-</KBD>&nbsp;</P>
</TD><TD valign=top style='width:35.9pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:23pt'>-</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:37pt'>368</KBD>&nbsp;</P>
</TD><TD valign=top style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>3.0</P>
</TD><TD valign=top style='width:52.1pt;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:37pt'>-</KBD>&nbsp;</P>
</TD><TD valign=top style='width:37.45pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:25pt'>-</KBD>&nbsp;</P>
</TD><TD valign=top style='width:51.75pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:40pt'>3,684</KBD>&nbsp;</P>
</TD><TD valign=top style=width:13.5pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:32.2pt><P align=right style='font:11pt Times New Roman;margin:0'>7.3</P>
</TD></TR>
<TR><TD valign=top style=width:89.95pt><P style='font:11pt Times New Roman;margin:0'>UK:</P>
</TD><TD valign=top style=width:49.15pt><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:36pt'>175</KBD>&nbsp;</P>
</TD><TD valign=top style='width:35.9pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:23pt'>-</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:37pt'>179</KBD>&nbsp;</P>
</TD><TD valign=top style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style='width:52.1pt;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:37pt'>724</KBD>&nbsp;</P>
</TD><TD valign=top style='width:37.45pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:25pt'>-</KBD>&nbsp;</P>
</TD><TD valign=top style='width:51.75pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:40pt'>678</KBD>&nbsp;</P>
</TD><TD valign=top style=width:13.5pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:32.2pt><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
<TR><TD valign=top style=width:89.95pt><P style='font:11pt Times New Roman;margin:0'>US:</P>
</TD><TD valign=top style=width:49.15pt><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:36pt'>949</KBD>&nbsp;</P>
</TD><TD valign=top style='width:35.9pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:23pt'>-</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:37pt'>1,339</KBD>&nbsp;</P>
</TD><TD valign=top style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style='width:52.1pt;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:37pt'>4,477</KBD>&nbsp;</P>
</TD><TD valign=top style='width:37.45pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:25pt'>-</KBD>&nbsp;</P>
</TD><TD valign=top style='width:51.75pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:40pt'>4,091</KBD>&nbsp;</P>
</TD><TD valign=top style=width:13.5pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:32.2pt><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
<TR><TD valign=top style=width:89.95pt><P style='font:11pt Times New Roman;margin:0'>IRE:</P>
</TD><TD valign=top style=width:49.15pt><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:36pt'>91</KBD>&nbsp;</P>
</TD><TD valign=top style='width:35.9pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:23pt'>-</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:37pt'>95</KBD>&nbsp;</P>
</TD><TD valign=top style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style='width:52.1pt;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:37pt'>364</KBD>&nbsp;</P>
</TD><TD valign=top style='width:37.45pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:25pt'>-</KBD>&nbsp;</P>
</TD><TD valign=top style='width:51.75pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:40pt'>322</KBD>&nbsp;</P>
</TD><TD valign=top style=width:13.5pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:32.2pt><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
<TR><TD valign=top style=width:89.95pt><P style='font:11pt Times New Roman;margin:0'>AUS:</P>
</TD><TD valign=top style=width:49.15pt><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:36pt'>17</KBD>&nbsp;</P>
</TD><TD valign=top style='width:35.9pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:23pt'>-</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:37pt'>28</KBD>&nbsp;</P>
</TD><TD valign=top style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style='width:52.1pt;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:37pt'>115</KBD>&nbsp;</P>
</TD><TD valign=top style='width:37.45pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:25pt'>-</KBD>&nbsp;</P>
</TD><TD valign=top style='width:51.75pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:40pt'>134</KBD>&nbsp;</P>
</TD><TD valign=top style=width:13.5pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:32.2pt><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
<TR><TD valign=top style='width:89.95pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>CAN:</P>
</TD><TD valign=top style='width:49.15pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:36pt'>26</KBD>&nbsp;</P>
</TD><TD valign=top style='width:35.9pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:23pt'>-</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:37pt'>31</KBD>&nbsp;</P>
</TD><TD valign=top style='width:33.1pt;border-bottom:0.5pt solid #000000;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style='width:52.1pt;border-left:1.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:37pt'>124</KBD>&nbsp;</P>
</TD><TD valign=top style='width:37.45pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:25pt'>-</KBD>&nbsp;</P>
</TD><TD valign=top style='width:51.75pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:40pt'>130</KBD>&nbsp;</P>
</TD><TD valign=top style='width:13.5pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:32.2pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
<TR><TD valign=top style='width:89.95pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Total G&amp;A:</P>
</TD><TD valign=top style='width:49.15pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:36pt'>1,767</KBD>&nbsp;</P>
</TD><TD valign=top style='width:35.9pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:23pt'>19.3</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:37pt'>2,533</KBD>&nbsp;</P>
</TD><TD valign=top style='width:33.1pt;border-top:0.5pt solid #000000;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>20.5</P>
</TD><TD valign=top style='width:52.1pt;border-top:0.5pt solid #000000;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:37pt'>7,835</KBD>&nbsp;</P>
</TD><TD valign=top style='width:37.45pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:25pt'>19.2</KBD>&nbsp;</P>
</TD><TD valign=top style='width:51.75pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:40pt'>11,016</KBD>&nbsp;</P>
</TD><TD valign=top style='width:13.5pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:32.2pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>21.9</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Although the GBP-denominated IIA Amort-UK expense was the same in both years&#8217; periods, the USD increase was due to a stronger GBP FX rate. Looking forward, the approximate $2 million/ year IIA Amort-UK G&amp;A expense will be fully amortized in 1Q 2026. &nbsp; </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Income Before Tax (EBT)</FONT> </P>
<P style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:6pt'>EBT results from subtracting net non-operating expense (NOE) or adding net non-operating income (NOI) from or to, as applicable, OI. Consolidated 2024 EBT was $16,802 (41.1% of sales) compared to $20,089 (40.0% of sales) in 2023. Consolidated 4Q 2024 EBT was $3,614 (39.5% of sales) compared to $5,017 (40.7% of sales) in 4Q 2023. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:6pt'>NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) U.S. excise taxes on share repurchases; 3) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 4) income from rent of underutilized property, investment income and royalties received from licensing the Company&#8217;s technology. Negative NOE is NOI. Net NOI in 2024 was $3,208 compared to $3,312 NOI in 2023. Net NOI in 4Q 2024 was $684 compared to $1,073 NOI in 4Q 2023. The decrease in 2024 NOI was due primarily to a $200 excise tax on share repurchases and $232 lower rent income in Ireland, offset by $331 higher interest on cash balances despite the use of $20 million in cash to repurchase shares. NOI in 2024 as a percent of sales was 7.8% compared to 6.6% in 2023. </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'>EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Consolidated EBT excluding the remeasured bank balance currency gain or loss, interest expense, noncash effects of depreciation, amortization of intangible assets and stock option expense (&#8220;adjusted consolidated EBITDA&#8221;) were $19,852 for the year 2024 compared to $26,635 in 2023. <A name=_Hlk156468792 />Adjusted consolidated EBITDA in 4Q 2024 was $4,405 compared to $6,115 in 4Q 2023. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales was 48.5% for the year 2024 compared to 53.0% in 2023. UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales was 48.1% in 4Q 2024 compared to 49.6% in 4Q 2023. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Management believes that this operating performance metric provides meaningful supplemental information to both management and investors and confirms UTMD&#8217;s ongoing excellent financial performance. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number:</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:432pt;margin-left:5.4pt><TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2024</FONT></P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2023</FONT></P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> 2024</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> 2023</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>EBT</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>$3,614</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$5,017</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$16,802</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>$20,089</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Depreciation Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>201</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>158</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>730</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>624</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Femcare IIA Amortization Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>509</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>493</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>2,030</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>1,977</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>CSI IIA Amortization Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:21pt'>-&#160;</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>368</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:21pt'>-&#160;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>3,684</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Other Non-Cash Amortization Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'> 8</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>7</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>35</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>31</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Stock Option Compensation Expense</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>72 </P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>73</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>256</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>225</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Interest Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>-&#160;</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-&#160;</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-&#160;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>-&#160;</P>
</TD></TR>
<TR><TD valign=top style='width:207pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Remeasured Foreign Currency Balances</P>
</TD><TD valign=top style='width:49.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>(1)</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>(1)</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>5</P>
</TD></TR>
<TR><TD valign=top style='width:207pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>UTMD non-US GAAP EBITDA:</P>
</TD><TD valign=top style='width:49.5pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$4,405</P>
</TD><TD valign=top style='width:58.5pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$6,115</P>
</TD><TD valign=top style='width:58.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$19,852</P>
</TD><TD valign=top style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$26,635</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Net Income (NI)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>NI for the year 2024 of $13,874 (33.9% of sales) was 16.6% lower than NI of $16,635 (33.1% of sales) in 2023. NI in 4Q 2024 of $2,902 (31.7% of sales) was 32.3% lower than NI of $4,287 (34.8% of sales) in 4Q 2023. The average consolidated income tax provisions (as a % of the same period EBT) for the year 2024 and 2023 were 17.4% and 17.2% respectively, and were 19.7% and 14.6% in 4Q 2024 and 4Q 2023 respectively. The consolidated income tax provision rate varies as the mix in taxable income among U.S. and foreign subsidiaries with differing income tax rates differs from period to period. UTMD has consistently paid millions of dollars in income taxes annually. The UK increased its corporate income tax rate from 19% to 25% effective on April 1, 2023. Otherwise, the basic 2024 corporate income tax rates in each of the sovereignties were the same as in the prior year. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Earnings per share (EPS)</FONT>. </P>
<P style='font:11pt Times New Roman;margin:0'>Despite 19.0% lower OI for the 2024 year, diluted 2024 EPS of $3.961 compared to $4.574 in 2023 were just 13.4% lower. Diluted EPS in 4Q 2024 were $0.857 compared to $1.180 in 4Q 2023. The smaller decrease in EPS for the 2024 year compared to the decline in OI and a slightly higher income tax rate was due to higher NOI as a percentage of sales and fewer diluted shares. Diluted shares were 3,503,165 for the 2024 year compared to 3,637,071 in 2023. Diluted shares were 3,387,932 in 4Q 2024 compared to 3,632,064 in 4Q 2023. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The number of shares used for calculating 4Q 2024 and year 2024 EPS were higher than the December 31, 2024 outstanding shares balance of 3,335,156 because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee options. Outstanding shares at the end of calendar year 2024 of 3,335,156 compared to 3,629,525 at the end of 2023, a decline of 8.1%. The difference was due to share repurchases of 301,961 offset by 7,592 shares in employee option exercises </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style=font-size:11pt>during 2024. The total number of outstanding unexercised employee and outside director options at December 31, 2024 was 97,985 at an average exercise price of $73.77, including shares awarded but not yet vested. This compares to 84,301 unexercised option shares at the end of 2023 at an average exercise price of $74.56/ share, including shares awarded but not vested. </FONT></P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The number of shares added as a dilution factor for the year 2024 was zero compared to 8,303 in 2023. The number of shares added as a dilution factor for 4Q 2024 was zero compared to 2,539 in 4Q 2023. The number of shares added as dilution factors in 2024 was zero because the average exercise price was higher than the applicable period-ending market price. In November 2024, 24,600 non-qualified option shares were awarded to 47 employees and one new outside director at an exercise price of $64.09 per share. &nbsp;In October 2023, 19,000 non-qualified option shares were awarded to 48 employees at an exercise price of $77.07 per share. UTMD&#8217;s stock option plans continue to be an integral part of attracting and retaining productive employees. Over time, option plans have not been dilutive to stockholders, as the Company has consistently repurchased substantially more shares in the open market at lower prices than it has awarded in options.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD paid <A name=_Hlk156298844 />$1,038 ($0.300/share) in dividends to stockholders in 4Q 2024 compared to $1,071 ($0.295/share) paid in 4Q 2023. UTMD paid $4,260 ($1.20/share) in dividends to stockholders in 2024 compared to $4,282 ($1.18/ share) in dividends in 2023. Payments in 2024 were lower than in 2023 despite higher dividends per share as a result of share repurchases. As declared in November 2024, UTMD&#8217;s regular quarterly dividend was increased to $0.305 per share starting with a January 2025 payment. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>No shares were repurchased in 2023. In 2024, the following quarterly repurchases were made:</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:108pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'># Shares Repurchased</FONT></P>
</TD><TD valign=top style=width:103.5pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Average Cost/ Share</FONT></P>
</TD><TD valign=top style=width:99pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Total Cost [$K]</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P align=right style='font:11pt Times New Roman;margin:0'>1Q 2024</P>
</TD><TD valign=top style=width:108pt><P align=right style='font:11pt Times New Roman;margin:0'>43,108</P>
</TD><TD valign=top style=width:103.5pt><P align=center style='font:11pt Times New Roman;margin:0'>$69.37</P>
</TD><TD valign=top style=width:99pt><P align=right style='font:11pt Times New Roman;margin:0'>$2,990</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P align=right style='font:11pt Times New Roman;margin:0'>2Q 2024</P>
</TD><TD valign=top style=width:108pt><P align=right style='font:11pt Times New Roman;margin:0'>95,107</P>
</TD><TD valign=top style=width:103.5pt><P align=center style='font:11pt Times New Roman;margin:0'>$67.33</P>
</TD><TD valign=top style=width:99pt><P align=right style='font:11pt Times New Roman;margin:0'>6,403</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P align=right style='font:11pt Times New Roman;margin:0'>3Q 2024</P>
</TD><TD valign=top style=width:108pt><P align=right style='font:11pt Times New Roman;margin:0'>58,377</P>
</TD><TD valign=top style=width:103.5pt><P align=center style='font:11pt Times New Roman;margin:0'>$66.22</P>
</TD><TD valign=top style=width:99pt><P align=right style='font:11pt Times New Roman;margin:0'>3,866</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2024</FONT></P>
</TD><TD valign=top style=width:108pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>105,369</FONT></P>
</TD><TD valign=top style=width:103.5pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>$63.67</FONT></P>
</TD><TD valign=top style=width:99pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>6,709</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P align=right style='font:11pt Times New Roman;margin:0'>Year Total</P>
</TD><TD valign=top style=width:108pt><P align=right style='font:11pt Times New Roman;margin:0'>301,961</P>
</TD><TD valign=top style=width:103.5pt><P align=center style='font:11pt Times New Roman;margin:0'>$66.13</P>
</TD><TD valign=top style=width:99pt><P align=right style='font:11pt Times New Roman;margin:0'>$19,968</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. UTMD&#8217;s closing share price at the end of 2024 was $61.47, down 27.0% from the closing price of $84.22 at the end of 2023, and down 8.1% from the end of the prior calendar quarter. In comparison, the major stock market indices were all substantially higher for the year 2024: the Dow Jones Industrial Average was up 12.9%, the S&amp;P 500 Index up 23.3% and the NASDAQ Composite, in which UTMD shares are traded, up 28.6%. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Balance Sheet</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>Please see the December 31, 2024 Balance Sheet at the end of this report. At the end of 2024, UTMD&#8217;s cash and investments at $83.0 million were $9.9 million lower than at the end of 2023 as a result of $19.9 million operating EBITDA minus $4.6 million paid in taxes, $4.3 million paid in cash dividends paid to stockholders, $20.0 million used to repurchase shares and a $0.9 million increase in non-cash working capital. The higher non-cash working capital was in spite of a $0.8 million decrease in inventories previously set as a hedge against supply chain disruptions. At December 31, 2024, Net Intangible Assets decreased $2.2 million to 13.4% of total consolidated assets from 13.8% on December 31, 2023. &nbsp;UTMD&#8217;s consolidated Property, Plant and Equipment (PPE) net asset value declined $790 despite just $499 in 2024 depreciation minus new PPE purchases as a result of year-end weakness in OUS FX rates translating OUS asset values to USD.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Financial ratios as of December 31, 2024 which may be of interest to stockholders follow:</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>Current Ratio = 25.6&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>Days in Trade Receivables (based on 4Q 2024 sales activity) = 40.3&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Average Inventory Turns in 2024 (based on 2024 CGS) = 1.8&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>4)</KBD>2024 ROE (before dividends) = 11.3%&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. &nbsp;Risk factors that could cause results to differ materially from those projected include global economic conditions, market acceptance of UTMD&#8217;s products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare in general, tax reforms, the Company&#8217;s ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD&#8217;s public disclosure filings with the SEC. &nbsp;UTMD&#8217;s 2024 SEC Form 10-K will be filed on or before March 29, 2025, and can be accessed on <FONT style='color:#215E99;border-bottom:1px solid #215E99'><B>www.utahmed.com</B></FONT>. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. &nbsp;For more information about Utah Medical Products, Inc., visit UTMD&#8217;s website at<B><I> </I></B><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><B>www.utahmed.com</B></FONT>.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-size:13pt><B>Utah Medical Products, Inc.</B></FONT></P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>INCOME STATEMENT, Fourth Quarter (three months ended December 31)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share):</P>
<TABLE style=border-collapse:collapse;width:360.9pt><TR><TD valign=top style=width:149.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2024</FONT></P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2023</FONT></P>
</TD><TD valign=top style=width:73.65pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 9,157</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$12,333</P>
</TD><TD valign=top style=width:73.65pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;(25.8%)</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>5,323</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>7,098</P>
</TD><TD valign=top style=width:73.65pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;(25.0%)</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>2,930</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>3,944</P>
</TD><TD valign=top style=width:73.65pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;(25.7%)</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>3,614</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>5,017</P>
</TD><TD valign=top style=width:73.65pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;(28.0%)</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt Times New Roman;margin:0'>Net Income</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>2,902</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>4,287</P>
</TD><TD valign=top style=width:73.65pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;(32.3%)</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt Times New Roman;margin:0'>Diluted EPS</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$0.857</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$1.180</P>
</TD><TD valign=top style=width:73.65pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;(27.4%)</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>3,388</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>3,632</P>
</TD><TD valign=top style=width:73.65pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>INCOME STATEMENT, Twelve Months (Calendar Year ended December 31)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share): </P>
<TABLE style=border-collapse:collapse;width:366.75pt><TR><TD valign=top style=width:144.9pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2024</FONT></P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2023</FONT></P>
</TD><TD valign=top style=width:76.5pt><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 40,903</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 50,224</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;(18.6%)</P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>24,143</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>30,038</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;(19.6%)</P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>13,594</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>16,777</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;(19.0%)</P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>16,802</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>20,089</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;(16.4%)</P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt Times New Roman;margin:0'>Net Income</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>13,874</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>16,635</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;(16.6%)</P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt Times New Roman;margin:0'>Diluted EPS</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 3.961</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 4.574</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;(13.4%)</P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>3,503</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>3,637</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0pt'>BALANCE SHEET</KBD><KBD style=margin-left:252pt></KBD> &nbsp;</P>
<TABLE style=border-collapse:collapse><TR style=height:21.6pt><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>(in thousands)</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2024</FONT></P>
</TD><TD valign=top style=width:90pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>SEP 30, 2024</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2023</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Assets</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:9.9pt><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Cash &amp; Investments</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>$82,976</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>$88,452</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$92,868</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Accounts &amp; Other Receivables, Net</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>4,095</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>3,720</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>3,391</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Inventories</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>8,812</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>9,107</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>9,582</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Other Current Assets</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>448</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>377</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>428</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>96,331</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>101,656</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>106,269</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>Property &amp; Equipment, Net</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>9,762</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>10,419</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>10,552</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>Intangible Assets, Net</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>16,445</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>17,619</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>18,637</FONT></P>
</TD></TR>
<TR style=height:21.15pt><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>$122,538</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>$129,694</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$135,458</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Liabilities &amp; Stockholders&#8217; Equity</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>Accounts Payable</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;696</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;999</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;769</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>REPAT Tax Payable</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>698</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>558</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>558</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>Other Accrued Liabilities</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2,363</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1,878</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3,383</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Total Current Liabilities</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$3,757</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$3,435</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$4,710</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>Deferred Tax Liability &#8211;&nbsp;Intangible Assets</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>604</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>779</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>1,120</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>Long Term Lease Liability </P>
<P style='font:10pt Times New Roman;margin:0'>Long Term REPAT Tax Payable</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>282</P>
<P align=center style='font:10pt Times New Roman;margin:0;margin-left:36pt'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>299</P>
<P align=right style='font:10pt Times New Roman;margin:0'>698</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>295</P>
<P align=right style='font:10pt Times New Roman;margin:0'>698</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>Deferred Revenue and Income Taxes</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>468</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>286</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>322</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>Stockholders&#8217; Equity</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>117,427</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>124,197</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>128,313</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities &amp; Stockholders&#8217; Equity</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>$122,538</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>$129,694</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$135,458</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>utmd-20250128_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEWPD92X]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20250128"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20250128.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>utmd-20250128_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEWPD92X]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20250128"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SolicitingMaterial' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Soliciting Material</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SolicitingMaterial' xlink:to='lab_dei_SolicitingMaterial'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Period End date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current with reporting</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementTenderOffer' xlink:to='lab_dei_PreCommencementTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Securities Act File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementIssuerTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Issuer Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementIssuerTenderOffer' xlink:to='lab_dei_PreCommencementIssuerTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SEC Form</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common stock shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax Identification Number (TIN)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Exchange</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant CIK</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_WrittenCommunications' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Written Communications</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_WrittenCommunications' xlink:to='lab_dei_WrittenCommunications'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fiscal Year End</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>utmd-20250128_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEWPD92X]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20250128"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20250128.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_WrittenCommunications' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SolicitingMaterial' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementTenderOffer' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementIssuerTenderOffer' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='33.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>utmd-20250128.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEWPD92X]. www.edgarsuite.com -->
<schema attributeFormDefault='unqualified' elementFormDefault='qualified' targetNamespace='http://utahmed.com/20250128' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:fil='http://utahmed.com/20250128' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:dei='http://xbrl.sec.gov/dei/2024'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250128_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250128_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250128_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2022-03-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2022-03-31'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='https://xbrl.sec.gov/dei/2024/dei-2024.xsd' namespace='http://xbrl.sec.gov/dei/2024'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45229895439136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 28, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Registrant CIK</a></td>
<td class="text">0000706698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">SEC Form</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Period End date</a></td>
<td class="text">Jan. 28,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Tax Identification Number (TIN)</a></td>
<td class="text">87-0342734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">000-12575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,IZ/%H'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #*>CQ:U5Y/&^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)\FB:.CVHGA2$%Q0O(5D=C=L\X=DI-VWMZV[740?P&-F?OGF
M&YC&)&5BQI<<$V9R6*X&WX6B3%JS/5%2 ,7LT>M2CXDP-K<Q>TWC,^\@:7/0
M.P3)^0UX)&TU:9B 55J(K&VL42:CIIA/>&L6?/K,W0RS!K!#CX$*B%H :Z>)
MZ3AT#5P $XPP^_)=0+L0Y^J?V+D#[)0<BEM2?=_7_6K.C3L(>']^>IW7K5PH
MI(/!\5=QBHX)U^P\^6UU_[!Y9*WD\KKBHI*W&\F5E$K<?4RN/_PNPCY:MW7_
MV/@LV#;PZR[:+U!+ P04    " #*>CQ:F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M ,IZ/%IMLWT.[P,  )\.   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9=K;^(X%(;_BI655KM2VUP(EW8!B=)VAYU>4*%;:;^YB0%K'#MC.Z7]]WL<
M(.G,A).1A@\D3GS>/#D^?AT/MTI_,1O&+'G+A#0C;V-M?N'[)MFPC)HSE3,)
M=U9*9]1"4Z]]DVM&TS(H$WX4!#T_HUQZXV%Y;:['0U58P26;:V**+*/Z_9()
MM1UYH7>X\,C7&^LN^.-A3M=LP>Q3/M?0\BN5E&=,&JXDT6PU\B;AQ654!I0]
M_N5L:SZ<$_<J+TI]<8U9.O("1\0$2ZR3H'!X95,FA%,"CJ][4:]ZI@O\>'Y0
MORE?'E[FA1HV5>*9IW8S\@8>2=F*%L(^JNTGMG^AKM-+E##E/]GN^L:Q1Y+"
M6)7M@X$@XW)WI&_[1'P(B 9' J)]0%1R[QY44EY12\=#K;9$N]Z@YD[*5RVC
M 8Y+-RH+J^$NAS@[OE)) 4FVA,J47$O+[3N9R=UH0]:&OH6'N*Y^LA>\W E&
M1P3_H?*,1(,3$@51]]MP']@JP*@"C$J]SC% 9BD7I@ED%Q@W![IROC Y3=C(
M@WHU3+\R;_S[;V$O^ O!ZE18'4Q]_,C6W%A-(7/3V><F.CP^@%\_Z/7.!PA,
M7,'$/PMS3S/61(,+/"TGG\C=]=5L.KDE\\>'JZ?I<G%"9O?3,P2O6^%U4?7%
M]92X*=3$A4<.3C\CS^]5S^^A*G.FN7+5G9*4VL;TX )53;<5=;\BZJ."2_I&
M9BE,.[[B23G1R'V1O3!-_EC.[O]L(L0%!_W3H!-'_4Z,T TJN@$J=ITQO>9R
M3?Z&0+LA4Y7E5+XW4>%"*RH,0X#.*Z!S'.C@2XG2N=)EPD[(PL)@$J6!KY!6
MO\,Q;1Q<7/QIB1"&0>VC 5[D+"DTMYP9,DDLN>&"[<>TT4-Q,3"'TS#J]K%:
M"S]8?/@SZ9ND*?B@.3F<D%OH1QYD8\Y:)/M!W"$+6.4WI!,$Y)D9BZ'69A^B
MIOT#ZM2U8(B7:MN\%N%R=SQ]I0(KP; V_!!W[._1JO*;:_7*9=*<1EP3K[W:
M_D/<OK]'FRMCJ2#_\?SHG&A1',1!W,?8:N\/<0LO1W "'XS'45K6@"#$0.I%
M(,1-_%8ED)/Y1DET8N(BW5X/)F808$3U(A#BIOT,?F&9=/Z:%7*_$#1^Z;0(
MM?EL6#M_B#OV0@F>@(N!^=]!>6M.12//K_E^6!M_B)OS7+/3!-+#8'Z5GZE+
M)E-8)A]6JR/CA^NUD46UWT>X1?] -C.F +(VP!;95L#:]2/<HB= E99D-X*N
M&U%P@:,H_H?MAMNZW5'WN6"(8"L0"L[Z,*'U;C>T:UB5ESN0%V5A/U.>;F '
MR;3K /=72ME#PVUJJCWI^']02P,$%     @ RGH\6I^@&_"Q @  X@P   T
M  !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV
M!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-S
MS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.
MIM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#
M%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6
M#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#H
MG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5<D].)3"6T@L-5)](1&,80)"L2_
MC!9B7X2]_:VPI!&/QGWL_&[TH'_OC./WEE>B'_2^FO-CT1=X=-8T\O1!BEHK
M'O;^RPF+-9O\R-%8\>2SP:0<O(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?
MK7/--;=,7I+VH_\W5_DMC)/Q]%P<T:L#.EL)7(0;^A7N5WGF0/:=D$[H43N*
MLN3ZQ3GUX1W;^PO\*KY?7_**==+M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[:)'-
MM[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1' L#P8 \PG>&%Y_J?]
MK-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7
MCX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L
M"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^\?Y@IR1-\SR. !9G
MD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ RGH\6I>*
MNQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q
M%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(
MMB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!
M;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B
M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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MOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ RGH\6@=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #*
M>CQ:U5Y/&^X    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #*>CQ:F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,IZ/%IMLWT.
M[P,  )\.   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " #*>CQ:GZ ;\+$"  #B#   #0
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:+GAM;%!+!08     "0 ) #X"  "2$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="utmd-20250128.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="utmd-20250128.htm">utmd-20250128.htm</File>
    <File>utmd-20250128.xsd</File>
    <File>utmd-20250128_def.xml</File>
    <File>utmd-20250128_lab.xml</File>
    <File>utmd-20250128_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "utmd-20250128.htm": {
   "nsprefix": "fil",
   "nsuri": "http://utahmed.com/20250128",
   "dts": {
    "inline": {
     "local": [
      "utmd-20250128.htm"
     ]
    },
    "schema": {
     "local": [
      "utmd-20250128.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20250128_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20250128_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20250128_pre.xml"
     ]
    }
   },
   "keyStandard": 19,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 34,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 19
   },
   "report": {
    "R1": {
     "role": "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation",
     "longName": "000010 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "D250128",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250128.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250128",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250128.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiscal Year End",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period End date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Form",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant CIK",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock shares outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current with reporting",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Identification Number (TIN)",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary filer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Exchange",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://utahmed.com/20250128/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001096906-25-000095-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001096906-25-000095-xbrl.zip
M4$L#!!0    ( ,IZ/%I9(1VYJ@X  &-D   1    =71M9"TR,#(U,#$R."YH
M=&WM'6MSVS;R>W\%3IVV]HU)D=1;MM5193G5Q:^1E4OF.IT.1$(6&HI@"="2
M^NMO%Z0>?DB6+$5Q'3N3F(_%8K'8-P#FZ.?1P">W+))<!,<_V:;U$V&!*SP>
MW!S_5+]NM%H__5S[[JBO  Q  WF<Z2L55K/9X7!H#G.FB&ZR=J52R8X0)I,
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MS7ICY'\5GBUWZX70?#XLB+JGOP%02P,$%     @ RGH\6DY;,1,7 @  )@<
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M TV 256 !;H V2BK$8.VCXQB2W3;=%7&LB%<]ASQ,L-C''ZX6C#?U,F;<ZO
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MH%J4EN^"+2.Z)KT_W\L;S!_SSR3G>_\"4$L#!!0    ( ,IZ/%H,6\#0JCX
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MOVQLY%J.7J8]&;G'NNK6,'(]>K.].'15?95H:DF1-LVOX6#'E1N_G;NY[I"
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M,-RDNP[K&3;*GKF[V\13*F$J&]HKK%O*,"H@73WTN?Y*QM;H1K%;<FKZ*?J
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M)Q%L2E2PB I"J9FF\_0]IZM*R"7?K.Q]H55Y,TN*6,D((TRX]P153RPOM\2
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M04A-4Y=88CDG0M-5^@)#3T.!<#?CF'DPG *13SP/XRP&PT>7JI7E)8Q,H/-
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M 5!+ 0(4 Q0    ( ,IZ/%I9(1VYJ@X  &-D   1              "  0
M  !U=&UD+3(P,C4P,3(X+FAT;5!+ 0(4 Q0    ( ,IZ/%K+"1/OS0(  /0(
M   1              "  =D.  !U=&UD+3(P,C4P,3(X+GAS9%!+ 0(4 Q0
M   ( ,IZ/%I.6S$3%P(  "8'   5              "  =41  !U=&UD+3(P
M,C4P,3(X7V1E9BYX;6Q02P$"% ,4    " #*>CQ:5PB]B# (  #:3@  %0
M            @ $?%   =71M9"TR,#(U,#$R.%]L86(N>&UL4$L! A0#%
M  @ RGH\6A'J*7^J!0  1C0  !4              ( !@AP  '5T;60M,C R
M-3 Q,CA?<')E+GAM;%!+ 0(4 Q0    ( ,IZ/%H,6\#0JCX  */: 0 /
M          "  5\B  !U=&UD7V5X.3EZ,2YH=&U02P4&      8 !@"$ 0
&-F$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>utmd-20250128_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20250128.xsd" xlink:type="simple"/>
    <context id="D250128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2025-01-28</startDate>
            <endDate>2025-01-28</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="D250128" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="D250128" id="fact2">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="D250128" id="ixv-352">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="D250128" id="ixv-353">2025-01-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="D250128" id="ixv-354">UTAH MEDICAL PRODUCTS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D250128" id="ixv-355">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="D250128" id="ixv-356">000-12575</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="D250128" id="ixv-357">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D250128" id="ixv-358">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D250128" id="ixv-359">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D250128" id="ixv-360">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D250128" id="ixv-361">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D250128" id="ixv-362">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D250128" id="ixv-363">566-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="D250128" id="ixv-364">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="D250128" id="ixv-365">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="D250128" id="ixv-366">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="D250128" id="ixv-367">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="D250128" id="ixv-368">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
